MASTNCT01050296
Molecular Analysis Of Solid Tumors
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 4 years later.
See at-risk trials from St. Jude Children's Research Hospital
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 27 versions: 19 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 30, 2026 to Sep 30, 2030 Show 5 more changesShow less
- Eligibility criteria expanded, about 6 words
- Study completion pushed from Sep 30, 2026 to Sep 30, 2035
- Study description revised
- Site details revised
- Collaborators: details revised at 1 of 1 entry
- Notable Primary and study completion dates: Sep 30, 2025 to Sep 30, 2026v26
- Notable Primary and study completion dates: Sep 30, 2024 to Sep 30, 2025v25
- Notable Enrollment target: 400 to 1000
- Primary and study completion dates: Sep 30, 2022 to Sep 30, 2024
- Notable Primary and study completion dates: Sep 2017 to Sep 30, 2022
- Eligibility criteria expanded, about 20 words
- Start date: Jan 2010 to Feb 10, 2010
Show 13 earlier versionsHide 13 earlier versions
- Notable Primary and study completion dates: Sep 2016 to Sep 2017
- Enrollment target: 360 to 400
- Minor Primary and study completion dates: Mar 2016 to Sep 2016v15
- Minor Primary and study completion dates: Sep 2015 to Mar 2016v14
- Minor Site contact updatedv13
- Notable Eligibility criteria shortened, about 33 wordsv12
- Notable Eligibility criteria shortened, about 39 words
- Secondary endpoints: 12 to 13
- Study description expanded, about 4 words
- Collaborators expanded, about 4 words
- Minor Site contact updatedv8
Notable Eligibility criteria expanded, about 2 wordsv7 Show 4 more changesShow less
- Enrollment target: 500 to 360
- Study sites: 3 to 1
- Primary endpoint revised
- Study description expanded, about 7 words
- Notable Eligibility criteria expanded, about 29 words
- Secondary endpoints: 11 to 12
- Study arms: 5 to 6
- Study description expanded, about 2 words
- Notable Eligibility criteria expanded, about 8 words
- Secondary endpoints revised (11)
- Notable Eligibility criteria expanded, about 11 wordsv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 3 of 3 sites
- Notable Primary endpoint revised
- Secondary endpoints revised (11)
- Study description expanded, about 25 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Perform analysis of gene expression profiles. [RNA] ribonucleic acid will be isolated from fresh frozen tumor specimens and hybridized to Affymetrix gene expression arrays.
Timeframe: 5 years
Secondary (13)
Perform analysis of large chromosomal alterations such as amplifications and deletions. [DNA] deoxyribonucleic acid isolated from the tumor and blood samples will be hybridized to array [CGH] comparative genomic hybridization chips.
Perform analysis of focal alterations in the genome including amplification, deletion and loss of heterozygosity (LOH). DNA isolated from the tumor and blood samples will be hybridized to [SNP] single nucleotide polymorphism chips.
Perform analysis of point mutations. DNA isolated from the tumor and blood samples will be sequenced using next-generation sequencing technology to determine the sequence of the entire genome.
Perform analysis of cell morphology. Tissue samples will be fixed in a buffer suitable for transmission electron microscopy and processed for [TEM] transmission electron microscopy analysis.
Compare micro RNAs in tumors. Micro RNAs will be isolated from the total [RNA] ribonucleic acid left over from the gene expression analysis described above. These samples will be used for micro [RNA] chip analysis or deep sequencing.
Show 8 moreShow less
Compare epigenetic modifications of [DNA] deoxyribonucleic acid. Genomic DNA will be isolated and DNA methylation will be analyzed across the genome to determine if this epigenetic process is altered in the tumor samples.
Compare epigenetic modifications of chromatin. Cells will be rapidly fixed and chromatin will be prepared in order to directly probe protein-DNA complexes by [ChIP-seq]chromatin immunoprecipitation or [ChIP-chip analysis] chromatin immunoprecipitation
Perform protein analysis. Tumor cells will be rapidly frozen for subsequent isolation of total protein or specific fraction of cellular proteins (i.e. nuclear, cytoplasmic, membrane proteins).
Perform immunohistochemical and FISH analysis of neuroblastoma, osteosarcoma, retinoblastoma, ESFT and soft tissue sarcomas. Tissue microarrays will be prepared from samples collected in this study.
Cell isolates obtained from primary and metastatic tumor specimens will be used to establish cell lines and orthotopic xenografts in immunocompromised mice.
Perform analysis of cell growth, metastasis and sensitivity to chemotherapy.
Evaluate the extent of immune cell infiltration and their functional status in pediatric solid tumors utilizing flow cytometric analysis of fresh tumor samples.
Evaluate tumor-associated macrophages (TAMSs) post-therapy to locate gene expression patterns, markers and functional correlates of the tissue repair properties of macrophages in the post-therapy microenvironment.
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States